Omalizumab safety concerns-Reference-Cited by-同舟云学术

Omalizumab safety concerns

Published:2025-01 Issue:1 Volume:155 Page:31-35
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Pongdee Thanai,Li James T.

Publisher

Elsevier BV

Reference27 articles.

1. Humanization of an antibody directed against IgE;Presta;J Immunol,1993

2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma;Agache;Allergy,2020

3. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study;Gevaert;J Allergy Clin Immunol,2022

4. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials;Wu;BMJ Open,2021

5. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials;Zhao;J Allergy Clin Immunol,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant Activation of Mast Cells: Molecular Mechanisms and Targets for Intervention;Clinical Reviews in Allergy & Immunology;2025-06-20

2. Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps;Journal of Allergy and Clinical Immunology;2025-05

3. Research progress of anti-IGE treatment for allergic rhinitis;American Journal of Otolaryngology;2025-05

4. Diagnostik und medikamentöse Therapie der chronischen Rhinosinusitis;HNO;2025-04-16

5. Omalizumab: The journey of the first anti-IgE approved for asthma and allergic disorders;Journal of Allergy and Clinical Immunology;2025-01